CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management 2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC)he management of patients with) Percutaneous coronary intervention using a combination of robotics and telecommunications by an operator in a separate physical location from the patient: an early exploration into the feasibility of telestenting (the REMOTE-PCI study) Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation The mSToPS Randomized Clinical Trial Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials Select Drug-Drug Interactions With Direct Oral Anticoagulants Sudden Cardiac Arrest Survivorship: A Scientific Statement From the American Heart Association The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability

Original ResearchVolume 114, August 2021, Pages 11-24

JOURNAL:Trends Food Sci Technol. Article Link

Potential protective mechanisms of green tea polyphenol EGCG against COVID-19

Y Zhang, B Wernly, ZCh Zhou et al. Keywords: COVID-19; prevention; green tea; EGCG

ABSTRACT

BACKGROUND - The world is in the midst of the COVID-19 pandemic. In this comprehensive review, we discuss the potential protective effects of ()-epigallocatechin-3-gallate (EGCG), a major constituent of green tea, against COVID-19.


SCOPE AND APPROACH - Information from literature of clinical symptoms and molecular pathology of COVID-19 as well as relevant publications in which EGCG shows potential protective activities against COVID-19 is integrated and evaluated.


KEY FINDINGS AND CONCLUSIONS - EGCG, via activating Nrf2, can suppress ACE2 (a cellular receptor for SARS-CoV-2) and TMPRSS2, which mediate cell entry of the virus. Through inhibition of SARS-CoV-2 main protease, EGCG may inhibit viral reproduction. EGCG via its broad antioxidant activity may protect against SARS-CoV-2 evoked mitochondrial ROS (which promote SARS-CoV-2 replication) and against ROS burst inflicted by neutrophil extracellular traps. By suppressing ER-resident GRP78 activity and expression, EGCG can potentially inhibit SARS-CoV-2 life cycle. EGCG also shows protective effects against 1) cytokine storm-associated acute lung injury/acute respiratory distress syndrome, 2) thrombosis via suppressing tissue factors and activating platelets, 3) sepsis by inactivating redox-sensitive HMGB1, and 4) lung fibrosis through augmenting Nrf2 and suppressing NF-κB. These activities remain to be further substantiated in animals and humans. The possible concerted actions of EGCG suggest the importance of further studies on the prevention and treatment of COVID-19 in humans. These results also call for epidemiological studies on potential preventive effects of green tea drinking on COVID-19.